PARP Inhibitors Cancer Review
45.6K views | +11 today
Follow
PARP Inhibitors Cancer Review
Poly ADP ribose polymerase (PARP) inhibitors for triple negative breast cancer (TNBC) The Phase III failure of Iniparib to extend OS or PFS in TNBC patients has cast a dark shadow on PARP inhibitors drug class and R&D in one of the most active area in industrial oncology. The most advanced product iniparib (BSI 201, Sanofi Aventis) has shown 30% response rates in Phase I trials and 62% in triple negative breast cancer patients in Phase II trials. Addition of Iniparib to chemotherapy increased overall survival to 12.2 months from 7.7 months on gemcitabine+ carboplatin. A global Phase III trial in squamous NSCLC was initiated in 2010. It has completed enrollment of TNBC patients in Phase III trials. The NDA and MAA is expected to be filed in 1-2 Q 2011. The second product olaparib has shown 40% response rates in extended Phase I trials and completed Phase II studies. Olaparib planned Phase III trials in BRCA1/BRCA2 positive breast cancer was cancelled by Astra Zeneca and focus shifted to Phase III in ovarian cancer patients. Olaparib extended PFS and time to progression by 4 and 4.6 months over placebo. Veliparib from Abbott is the third PARPi to complete Phase II trials in advanced metastatic breast cancer with 37% RR in BRCA positive patients. Tumor cells use PARP pathway to repair DNA damage to proliferate and replicate. A new test to identify defective genes RAD51 assay indicates that PARP inhibitors may benefit 60% of the ovarian cancer patients. Inhibition of PARP offers novel agents for treating tumors with DNA repair defects. PARP inhibitors have the market potential to generate 10-15 billion annual sales with each brand worth $3-5 billion in sales within 5 years after approval and marketing in major markets.
Curated by Krishan Maggon
Your new post is loading...
Your new post is loading...
Scooped by Krishan Maggon
Scoop.it!

Iniparib, Olaparib & Veliparib (PARPi) Breast Cancer Review - a knol by Krishan Maggon

Iniparib, Olaparib & Veliparib (PARPi) Breast Cancer Review - a knol by Krishan Maggon | PARP Inhibitors Cancer Review | Scoop.it
The Phase III failure of Iniparib to extend OS or PFS in TNBC patients has cast a dark shadow on PARP inhibitors drug class...
more...
Chuck's curator insight, January 20, 2015 12:50 PM

Sad to learn this but now no false hopes....

Scooped by Krishan Maggon
Scoop.it!

Seeing the Unseen: Ultrasound's New Role in the Fight Against Breast Cancer - GE Reports

Seeing the Unseen: Ultrasound's New Role in the Fight Against Breast Cancer - GE Reports | PARP Inhibitors Cancer Review | Scoop.it
Patti Beyer is a positive person by nature. But the 64-year-old retired educator was concerned after she requested, and received, a breast ultrasound-screening exam.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Venetoclax for Chronic Lymphocytic Leukemia

Venetoclax for Chronic Lymphocytic Leukemia | PARP Inhibitors Cancer Review | Scoop.it
The FDA has approved venetoclax for patients with chronic lymphocytic leukemia (CLL) whose tumors have a specific genetic alteration.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Anti-VEGFR2 Driven Nuclear Translocation of VEGFR2 and Acquired Malignant Hallmarks are Mutation Dependent in Glioblastoma | Open Access | OMICS International

Anti-VEGFR2 Driven Nuclear Translocation of VEGFR2 and Acquired Malignant Hallmarks are Mutation Dependent in Glioblastoma | Open Access | OMICS International | PARP Inhibitors Cancer Review | Scoop.it
Anti-VEGFR2 Driven Nuclear Translocation of VEGFR2 and Acquired
Malignant Hallmarks are Mutation Dependent in Glioblastoma, Journal of Cancer Science & Therapy.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Targeting cancer cell metabolism with mitochondria-immobilized phosphorescent cyclometalated iridium(III) complexes - Chemical Science (RSC Publishing)

Targeting cancer cell metabolism with mitochondria-immobilized phosphorescent cyclometalated iridium(III) complexes - Chemical Science (RSC Publishing) | PARP Inhibitors Cancer Review | Scoop.it
Cancer cell metabolism is reprogrammed to sustain the high metabolic demands of cell proliferation. Recently, emerging studies have shown that mitochondrial metabolism is a potential target for cancer therapy.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Taxane + Anti-VEGF Effective for Nonsquamous NSCLC

Taxane + Anti-VEGF Effective for Nonsquamous NSCLC | PARP Inhibitors Cancer Review | Scoop.it
Chicago—When combined as second- or third-line therapy for nonsquamous non-small cell lung cancer (NSCLC), paclitaxel and bevacizumab extend progression-free survival (PFS) relative to docetaxel alone, accordin...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

CAR T Cell Therapy for Diffuse Large B Cell Lymphoma Included in EMA’s PRIority MEdicines Scheme | ESMO

CAR T Cell Therapy for Diffuse Large B Cell Lymphoma Included in EMA’s PRIority MEdicines Scheme | ESMO | PARP Inhibitors Cancer Review | Scoop.it
EMA’s new initiative to foster research on and development of medicines with potential to address an unmet medical need


more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

A polycomb-mediated epigenetic field defect precedes invasive cervical carcinoma | Wijetunga | Oncotarget

A polycomb-mediated epigenetic field defect precedes invasive cervical carcinoma | Wijetunga | Oncotarget | PARP Inhibitors Cancer Review | Scoop.it
A polycomb-mediated epigenetic field defect precedes invasive cervical carcinoma
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Next Generation Multiresponsive Nanocarriers for Targeted Drug Delivery to Cancer Cells - Altenbuchner - 2016 - Chemistry - A European Journal - Wiley Online Library

Next Generation Multiresponsive Nanocarriers for Targeted Drug Delivery to Cancer Cells - Altenbuchner - 2016 - Chemistry - A European Journal - Wiley Online Library | PARP Inhibitors Cancer Review | Scoop.it
C−H bond activation of 2-methoxyethylamino-bis(phenolate)-yttrium catalysts allowed the synthesis of BAB block copolymers comprised of 2-vinylpyridine (2VP; monomer A) and diethylvinylphosphonate (DEVP; monomer B) as the A and B blocks, respectively, by rare-earth-metal-mediated group-transfer polymerization (REM-GTP). The inherent multi-stimuli-responsive character and drug-loading and -release capabilities were observed to be dependent on the chain length and monomer ratios. Cytotoxicity assays revealed the biocompatibility and nontoxic nature of the obtained micelles toward ovarian cancer (HeLa) cells. The BAB block copolymers effectively encapsulated, transported, and released doxorubicin (DOX) within HeLa cells. REM-GTP enables access to previously unattainable vinylphosphonate copolymer structures, and thereby unlocks their full potential as nanocarriers for stimuli-responsive drug delivery in HeLa cells. The self-evident consequence is the application of these new micelles as potent drug-delivery vehicles with reduced side effects in future cancer therapies.
Multiresponsive BAB block copolymers based on 2-vinylpyridine and vinylphosphonates were synthesized by rare-earth-metal-mediated group-transfer polymerization (REM-GTP, see figure). Drug-loading-capability experiments with doxorubicin (DOX) and ovarian cancer (HeLa) cells demonstrated the biocompatibility of the vinylphosphonate carriers.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Safety and pharmacodynamics of the PDE4 inhibitor roflumilast in advanced B cell malignancies

Safety and pharmacodynamics of the PDE4 inhibitor roflumilast in advanced B cell malignancies | PARP Inhibitors Cancer Review | Scoop.it
Purpose:In this study, we aimed to validate our extensive pre-clinical data on phosphodiesterase 4 (PDE4) as actionable target in B-cell malignancies.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Epigenetics: Cancer and Beyond | The New York Academy of Sciences

Epigenetics: Cancer and Beyond | The New York Academy of Sciences | PARP Inhibitors Cancer Review | Scoop.it
RT @ReactionBiology: So much great work discussed! #cancer #epigenetics Epigenetics: Cancer and Beyond
https://t.co/MCKdlHkxoo
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

NIST and Frederick National Laboratory for Cancer Research Help Ensure Accurate Clinical Measurements of HER2 Breast Cancer Gene - Science and Technology Research News

NIST and Frederick National Laboratory for Cancer Research Help Ensure Accurate Clinical Measurements of HER2 Breast Cancer Gene - Science and Technology Research News | PARP Inhibitors Cancer Review | Scoop.it
A new measurement standard developed by the National Institute of Standards of Technology (NIST) has been used successfully by the Frederick National Laboratory for Cancer Research to check the performance of next-generation DNA-sequencing...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

OncoGenex Custirsen Fails Phase 3 AFFINITY Trial in Metastatic Castrate-Resistant Prostate Cancer 

OncoGenex Custirsen Fails Phase 3 AFFINITY Trial in Metastatic Castrate-Resistant Prostate Cancer  | PARP Inhibitors Cancer Review | Scoop.it
BOTHELL, Wash. and VANCOUVER, British Columbia, Aug. 16, 2016 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today results from the final analysis of AFFINITY, the Phase 3 trial of custirsen in men with metastatic castrate-resistant prostate cancer (CRPC) whose disease has progressed after treatment with docetaxel. The trial did not meet the primary endpoint of demonstrating a statistically significant improvement in overall survival for patients treated with custirsen in combination with cabazitaxel/prednisone compared to cabazitaxel/prednisone alone.
Krishan Maggon 's insight:
About Custirsen 

 Custirsen is a highly specific clusterin inhibitor designed to improve survival in patients with advanced cancer by disabling a fundamental cellular repair mechanism used by tumor cells. Custirsen binds to clusterin mRNA to block the production of clusterin protein and has enhanced the tumor cell destructive effects of multiple anti-cancer therapies across a variety of tumor models. By inhibiting clusterin, custirsen is designed to alter tumor dynamics by slowing tumor growth and inhibiting tumor resistance to partner treatments, so that the benefits of therapy, including survival, may be extended.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

F1000Research Article: Recent advances in understanding multiple myeloma.

F1000Research Article: Recent advances in understanding multiple myeloma. | PARP Inhibitors Cancer Review | Scoop.it
Read the latest article version by Binod Dhakal, Saulius Girnius, Parameswaran Hari, at F1000Research.

Abstract There have been major recent advancements in the understanding and management of multiple myeloma. Diagnostic criteria have been revised and former ultra-high-risk smoldering multiple myeloma is now considered multiple myeloma in need of treatment. Understanding clonal progression, evolution, and tides not only has helped elucidate the disease behavior but might help expand therapeutic choices in order to select appropriate treatment for patients. Unprecedented response rates with modern triplet induction therapies containing proteasome inhibitor and immunomodulators have made this approach standard for initial treatment. The US Food and Drug Administration approved four new drugs (two targeted antibodies and two oral agents) in 2015 in relapsed/refractory multiple myeloma and these drugs along with the other already-available drugs have now increased the choices of regimens. Even drugs without single-agent activity, such as panobinostat and elotuzumab, have an important role, especially in the proteasome inhibitor refractory setting. Recent studies done in the context of novel agent induction suggest that high-dose therapy followed by autologous transplant continues to improve response rates and progression-free survival, thus underscoring their role in transplant-eligible patients. Evolving paradigms in the treatment of multiple myeloma include newer promising immune approaches, such as adoptive cellular therapies, vaccines, or antibody-based immune manipulations. Though multiple myeloma is still considered incurable, it is clear that with the improved understanding of disease biology and clonal architecture of relapse combined with the availability of multi-targeted approaches, we are ever closer to a lasting cure or transformation into indolent and long-lasting disease courses or both.
Krishan Maggon 's insight:
Dhakal B, Girnius S and Hari P. Recent advances in understanding multiple myeloma [version 1; referees: 4 approved]. F1000Research 2016, 5(F1000 Faculty Rev):2053 (doi: 10.12688/f1000research.8777.1)
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

FDA priority review for Rucaparib (Clovis Oncology) NDA for ovarian cancer

FDA priority review for Rucaparib (Clovis Oncology) NDA for ovarian cancer | PARP Inhibitors Cancer Review | Scoop.it
BOULDER, Colo.--(BUSINESS WIRE)--Aug. 23, 2016-- Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the U.S. Food and Drug Administration (FDA) has accepted Clovis’ New Drug Application (NDA) for accelerated approval of rucaparib and granted priority review status to the application with a Prescription Drug User Fee Act (PDUFA) date of February 23, 2017. In late June 2016, Clovis completed its NDA submission of rucaparib to the FDA for the treatment of advanced ovarian cancer in patients with deleterious BRCA-mutated tumors inclusive of both germline and somatic BRCA mutations (as detected by an FDA-approved test), and who have been treated with two or more chemotherapies. Rucaparib was granted Breakthrough Therapy Designation for the proposed indication by the FDA in April 2015.

Foundation Medicine, Clovis’ companion diagnostic partner, has submitted a Premarket Approval (PMA) application for its FoundationFocus CDxBRCA to the FDA in June 2016. The test is designed to identify tumor BRCA mutations, including germline and somatic BRCA mutations. The timing of the submission is expected to allow for regulatory approval of the companion diagnostic in a similar timeframe.

The efficacy of rucaparib was assessed in 106 patients from two multicenter, single-arm, open-label clinical trials, Study 1 (Study 10, NCT01482715) and Study 2 (ARIEL2 Parts 1 and 2, NCT01891344), in patients with advanced BRCA-mutant ovarian cancer who had progressed after two or more prior chemotherapies. Median age was 59 years and median number of prior chemotherapy regimens was three. Study 1 was limited to platinum sensitive patients; Study 2 included platinum sensitive, platinum resistant and platinum refractory patients. All 106 patients received the starting dose of rucaparib 600 mg twice daily. The major efficacy outcome measure of both trials was objective response rate (ORR) and duration of response (DOR) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. All responses were confirmed.
Krishan Maggon 's insight:
Clovis gained $ 300 million in market value after the news.

Rucaparib is a small molecule poly ADP-ribose polymerase (PARP) inhibitor that specifically binds to PARP-1 and PARP-2. PARPs are proteins that play a key role in repairing single-strand breaks in DNA. By inhibiting their action, multiple DNA breaks form during the replication process in tumor cells that have the BRCA1, BRCA2 or PALB2 mutation which leads to cell death.

Specifically, rucaparib is being developed as monotherapy treatment of advanced ovarian cancer in patients with deleterious BRCA-mutated tumors inclusive of both germline and somatic BRCA mutations (as detected by an FDA-approved test) who have been treated with two or more chemotherapies. Rucaparib was granted Breakthrough Therapy Designation for this proposed indication by the U.S. FDA in April 2015; and in late June 2016, Clovis completed its New Drug Application (NDA) submission to the FDA. The filing for treatment was accepted and has an action date of February 23, 2017. Rucaparib’s Marketing Authorization Application (MAA) to the European Medicines Agency for the proposed treatment indication is planned for Q4 2016. 

Additionally, rucaparib is being developed as maintenance therapy in the ARIEL3 trial (NCT01968213) for patients with tumors with BRCA mutations and other DNA repair deficiencies beyond BRCA (commonly referred to as homologous recombination deficiencies, or HRD). Data from ARIEL3 are expected in Q4 2017, which is expected to be followed by the submission of a supplemental NDA for second-line maintenance therapy. Clovis is also exploring rucaparib in other solid tumor types with BRCA and HRD populations, including prostate, breast and gastroesophageal cancers.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Recurrent, truncating Sox9 mutations are associated with sox9 overexpression, KRAS mutation, and TP53 wild type status in colorectal carcinoma | Javier | Oncotarget

Recurrent, truncating Sox9 mutations are associated with sox9 overexpression, KRAS mutation, and TP53 wild type status in colorectal carcinoma | Javier | Oncotarget | PARP Inhibitors Cancer Review | Scoop.it
Recurrent, truncating Sox9 mutations are associated with sox9 overexpression, KRAS mutation, and TP53 wild type status in colorectal carcinoma

ABSTRACT 

 Purpose: The extent to which the developmental transcription factor SOX9 functions as an oncogene or tumor suppressor in colorectal carcinoma (CRC) is debatable. We aimed to clarify the effect of SOX9 mutations on SOX9 protein expression and their association with known molecular subtypes and clinical characteristics in advanced CRC. 

Experimental Design: Next generation sequencing data (MSK-IMPACT) from CRC patients was used to interrogate SOX9, KRAS, NRAS, BRAF, TP53, APC, and PIK3CA. Mutant and wild type (WT) SOX9 cases underwent immunohistochemical (IHC) staining to assess protein expression. SOX9 allele-specific copy number was assessed by Affymetrix Oncoscan array. 

Results: SOX9 was mutated in 38 of 353 (10.7%) CRC, of which 82% were frameshift or nonsense. Compared to SOX9 WT, SOX9 mutation was strongly associated with coexistent mutant KRAS (p=0.0001) and WT TP53 (p=0.0004). SOX9 was overexpressed in both SOX9 mutant and WT CRC. Among SOX9 mutants, the highest expression was noted for truncating exon 3 mutants (mean H scores 239±105 versus 147±119, p value=0.02). Further, SOX9 truncating mutants with loss of the WT allele demonstrated protein overexpression indicating the WT protein was not required for protein stabilization. 

Conclusions: SOX9 is overexpressed in CRC, including those with recurrent distal truncating mutations. The latter has structural similarity to the oncogenic isoform MiniSOX9, which is distally truncated due to aberrant splicing. This information suggests that truncated SOX9 has oncogenic features. SOX9 mutations are highly enriched in KRAS mutant and TP53 wild type CRC; and may provide a therapeutic target in approximately 11% of CRC.
Krishan Maggon 's insight:
DOI: 10.18632/oncotarget.9682

Breanna M. Javier1,2, Rona Yaeger3, Lu Wang1, Francisco Sanchez-Vega2, Ahmet Zehir1, Sumit Middha1, Justyna Sadowska1, Efsevia Vakiani1, Jinru Shia1, David Klimstra1, Marc Ladanyi1,2, Christine A. Iacobuzio-Donahue1,2 and Jaclyn F. Hechtman1
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Nanofiber scaffolds demonstrate new features in the behaviour of stem and cancer cells

Nanofiber scaffolds demonstrate new features in the behaviour of stem and cancer cells | PARP Inhibitors Cancer Review | Scoop.it
Novel scaffolds are shown enabling cells to behave in a different but controlled way in vitro due to the presence of aligned, self-assembled ceramic nanofibers of an ultra-high anisotropy ratio augmented into graphene shells.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Direct-to-Patient Research Recruitment Reaps Rewards

Direct-to-Patient Research Recruitment Reaps Rewards | PARP Inhibitors Cancer Review | Scoop.it
Chicago—Incredibly rapid enrollment in the Metastatic Breast Cancer Project, a national direct-to-patient outreach project to accelerate breast cancer research, has clinicians excited. In the first seve
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compounds | Carrella | Oncotarget

Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compounds | Carrella | Oncotarget | PARP Inhibitors Cancer Review | Scoop.it

Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compounds


ABSTRACT The discovery of inhibitors for oncogenic signalling pathways remains a key focus in modern oncology, based on personalized and targeted therapeutics. Computational drug repurposing via the analysis of FDA-approved drug network is becoming a very effective approach to identify therapeutic opportunities in cancer and other human diseases. Given that gene expression signatures can be associated with specific oncogenic mutations, we tested whether a “reverse” oncogene-specific signature might assist in the computational repositioning of inhibitors of oncogenic pathways. As a proof of principle, we focused on oncogenic PI3K-dependent signalling, a molecular pathway frequently driving cancer progression as well as raising resistance to anticancer-targeted therapies. We show that implementation of “reverse” oncogenic PI3K-dependent transcriptional signatures combined with interrogation of drug networks identified inhibitors of PI3K-dependent signalling among FDA-approved compounds. This led to repositioning of Niclosamide (Niclo) and Pyrvinium Pamoate (PP), two anthelmintic drugs, as inhibitors of oncogenic PI3K-dependent signalling. Niclo inhibited phosphorylation of P70S6K, while PP inhibited phosphorylation of AKT and P70S6K, which are downstream targets of PI3K. Anthelmintics inhibited oncogenic PI3K-dependent gene expression and showed a cytostatic effect in vitro and in mouse mammary gland. Lastly, PP inhibited the growth of breast cancer cells harbouring PI3K mutations. Our data indicate that drug repositioning by network analysis of oncogene-specific transcriptional signatures is an efficient strategy for identifying oncogenic pathway inhibitors among FDA-approved compounds. We propose that PP and Niclo should be further investigated as potential therapeutics for the treatment of tumors or diseases carrying the constitutive activation of the PI3K/P70S6K signalling axis.

Krishan Maggon 's insight:
Oncotarget   

Diego Carrella1, Isabella Manni3, Barbara Tumaini1, Rosanna Dattilo2 , Federica Papaccio3, Margherita Mutarelli1, Francesco Sirci1, Carla A. Amoreo4, Marcella Mottolese4, Manuela Iezzi5, Laura Ciolli5, Valentina Aria6, Roberta Bosotti7, Antonella Isacchi7, Fabrizio Loreni6, Alberto Bardelli8,9, Vittorio E. Avvedimento10, Diego di Bernardo1,11 and Luca Cardone3

Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compounds 

DOI: 10.18632/oncotarget.11318
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Dynamic clonal equilibrium and predetermined cancer risk in Barrett’s oesophagus

Dynamic clonal equilibrium and predetermined cancer risk in Barrett’s oesophagus | PARP Inhibitors Cancer Review | Scoop.it
Barrett’s oesophagus is thought to be a precursor lesion for oesophageal cancer, and predicting the benign lesions that progress to cancer is clinically important.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Survival and proliferation of neural progenitor derived glioblastomas under hypoxic stress is controlled by a CXCL12/CXCR4 autocrine positive feedback mechanism

Survival and proliferation of neural progenitor derived glioblastomas under hypoxic stress is controlled by a CXCL12/CXCR4 autocrine positive feedback mechanism | PARP Inhibitors Cancer Review | Scoop.it
Purpose: One likely cause of treatment failure in glioblastoma is the persistence of glioma stem-like cells (GSLCs), highly resistant to therapies currently employed. We found that CXCL12 has highest expression in glioma cells derived from neural progenitor cells (NPCs). The development and molecular signature of NPC-derived GBMs were analyzed and the therapeutic effect of blocking CXCL12 was tested. Experimental Design: Tumors were induced by injecting DNA into the lateral ventricle of neonatal mice, using the Sleeping Beauty transposase method. Histology and expression of GSLC markers were analyzed during disease progression. Survival upon treatment with pharmacologic (Plerixafor) or genetic inhibition of CXCR4 was analyzed. Primary neurospheres were generated and analyzed for proliferation, apoptosis and expression of proteins regulating survival and cell cycle progression. Results: Tumors induced from NPCs display histological features of human GBM and express markers of GSLC. In vivo, inhibiting the CXCL12/CXCR4 signaling axis results in increased survival of tumor-bearing animals. In vitro, CXCR4 blockade induces apoptosis and inhibits cell cycle progression, downregulates molecules regulating survival and proliferation and also blocks the hypoxic-induction of HIF-1α and CXCL12. Exogenous administration of CXCL12 rescues the drug-induced decrease in proliferation. Conclusions: This study demonstrates that the CXCL12/CXCR4 axis operates in GBM cells under hypoxic stress via an autocrine positive feedback mechanism, which promotes survival and cell cycle progression. Our study brings new mechanistic insight and encourages further exploration of the use of drugs blocking CXCL12 as adjuvant agents to target hypoxia-induced GBM progression, prevent resistance to treatment and recurrence of the disease.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

How Did Bristol-Myers Squibb’s Oncology Segment Perform in 2Q16? - Market Realist

How Did Bristol-Myers Squibb’s Oncology Segment Perform in 2Q16? - Market Realist | PARP Inhibitors Cancer Review | Scoop.it
Due to the strong performance of Opdivo, the oncology segment has emerged as the largest revenue contributor for Bristol-Myers Squibb (BMY) in 2Q16.
more...
No comment yet.
Rescooped by Krishan Maggon from Hematology
Scoop.it!

Atlas of Genetics and Cytogenetics in Oncology and Haematology

Atlas of Genetics and Cytogenetics in Oncology and Haematology | PARP Inhibitors Cancer Review | Scoop.it
The Atlas of Genetics and Cytogenetics in Oncology and Haematology gives reviews on genes involved in cancer, leukemias, solid tumors, and cancer-prone diseases. It also provides lectures in Genetics for students in medicine/sciences.

Via Gilbert C FAURE
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Advancing a Treatment for Acute Myeloid Leukemia | Leukemia and Lymphoma Society

Advancing a Treatment for Acute Myeloid Leukemia | Leukemia and Lymphoma Society | PARP Inhibitors Cancer Review | Scoop.it
In April we featured a Q&A in this blog with LLS-funded researcher Anthony Letai, MD, PhD, of Dana-Farber Cancer Institute, who discussed in his work leading to clinical trials of a drug called venetoclax (Venclexta ®) for acute myeloid leukemia (AML).
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Anthrax Toxin-Based Cancer Therapy Targets Tumor Blood Vessels

Anthrax Toxin-Based Cancer Therapy Targets Tumor Blood Vessels | PARP Inhibitors Cancer Review | Scoop.it
An NCI Cancer Currents blog on a study which shows that an anthrax toxin-based cancer therapy may attack tumors by selectively targeting blood vessels that feed them.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Blocking a human branched DNA enzyme offers new ways of targeting a crucial enzyme family for cancer - News releases - News - The University of Sheffield

Blocking a human branched DNA enzyme offers new ways of targeting a crucial enzyme family for cancer - News releases - News - The University of Sheffield | PARP Inhibitors Cancer Review | Scoop.it
An international team of scientists have discovered how compounds block flap endonuclease 1 (FEN1) - a crucial enzyme class in the DNA damage response and potential target for cancer treatment.
more...
No comment yet.